Tamoxifen in children with Duchenne muscular dystrophy

被引：0
作者：
Servais, Laurent [1 ,2 ,3 ,4 ]
机构：
[1] Univ Oxford, MDUK Oxford Neuromuscular Ctr, Oxford, England
[2] Univ Oxford, NIHR Oxford Biomed Res Ctr, Oxford, England
[3] Univ Hosp Liege, Ctr Reference Malad Neuromusculaires, Dept Pediat, Div Child Neurol, B-4000 Liege, Belgium
[4] Univ Liege, B-4000 Liege, Belgium
来源：
LANCET NEUROLOGY | 2023年 / 22卷 / 10期
关键词：
D O I：
10.1016/S1474-4422(23)00288-0
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：872 / 873
页数：2
相关论文
共 10 条
[1]   A state-of-the-art review of tamoxifen as a potential therapeutic for duchenne muscular dystrophy [J].
Botti, Valeria ;
Menzel, Olivier ;
Staedler, Davide .
FRONTIERS IN PHARMACOLOGY, 2022, 13
[2]   Safety and efficacy of tamoxifen in boys with Duchenne muscular dystrophy (TAMDMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial [J].
Henzi, Bettina C. ;
Schmidt, Simone ;
Nagy, Sara ;
Rubino-Nacht, Daniela ;
Schaedelin, Sabine ;
Putananickal, Niveditha ;
Stimpson, Georgia ;
Consortium, North Star ;
Amthor, Helge ;
Childs, Anne-Marie ;
Deconinck, Nicolas ;
de Groot, Imelda ;
Horrocks, Iain ;
Opstal, Saskia Houwen-van ;
Laugel, Vincent ;
Lobato, Mercedes Lopez ;
Garrido, Marcos Madruga ;
Osorio, Andres Nascimento ;
Schara-Schmidt, Ulrike ;
Spinty, Stefan ;
von Moers, Arpad ;
Lawrence, Fiona ;
Hafner, Patricia ;
Dorchies, Olivier M. ;
Fischer, Dirk .
LANCET NEUROLOGY, 2023, 22 (10) :890-899
[3]   Crowdfunding for neuromuscular disease treatment: the ethical implications [J].
Livingstone, Angus ;
Servais, Laurent ;
Wilkinson, Dominic J. C. .
LANCET NEUROLOGY, 2021, 20 (10) :788-789
[4]   Emerging therapies for Duchenne muscular dystrophy [J].
Markati, Theodora ;
Oskoui, Maryam ;
Farrar, Michelle A. ;
Duong, Tina ;
Goemans, Nathalie ;
Servais, Laurent .
LANCET NEUROLOGY, 2022, 21 (09) :814-829
[5]   Lessons Learned from Discontinued Clinical Developments in Duchenne Muscular Dystrophy [J].
Markati, Theodora ;
De Waele, Liesbeth ;
Schara-Schmidt, Urlike ;
Servais, Laurent .
FRONTIERS IN PHARMACOLOGY, 2021, 12
[6]   Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy A Nonrandomized Controlled Trial [J].
Mendell, Jerry R. ;
Sahenk, Zarife ;
Lehman, Kelly ;
Nease, Carrie ;
Lowes, Linda P. ;
Miller, Natalie F. ;
Iammarino, Megan A. ;
Alfano, Lindsay N. ;
Nicholl, Amanda ;
Al-Zaidy, Samiah ;
Lewis, Sarah ;
Church, Kathleen ;
Shell, Richard ;
Cripe, Linda H. ;
Potter, Rachael A. ;
Griffin, Danielle A. ;
Pozsgai, Eric ;
Dugar, Ashish ;
Hogan, Mark ;
Rodino-Klapac, Louise R. .
JAMA NEUROLOGY, 2020, 77 (09) :1122-1131
[7]   Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls [J].
Muntoni, Francesco ;
Signorovitch, James ;
Sajeev, Gautam ;
Goemans, Nathalie ;
Wong, Brenda ;
Tian, Cuixia ;
Mercuri, Eugenio ;
Done, Nicolae ;
Wong, Hallee ;
Moss, Jackson ;
Yao, Zhiwen ;
Ward, Susan J. ;
Manzur, Adnan ;
Servais, Laurent ;
Niks, Erik H. ;
Straub, Volker ;
de Groot, Imelda Jm ;
McDonald, Craig .
NEUROMUSCULAR DISORDERS, 2022, 32 (04) :271-283
[8]   Stride Velocity 95th Gentile: Insights into Gaining Regulatory Qualification of the First Wearable-Derived Digital Endpoint for use in Duchenne Muscular Dystrophy Trials [J].
Servais, Laurent ;
Yen, Karl ;
Guridi, Maitea ;
Lukawy, Jacek ;
Vissiere, David ;
Strijbos, Paul .
JOURNAL OF NEUROMUSCULAR DISEASES, 2022, 9 (02) :335-346
[9]   Safety and clinical outcome of tamoxifen in Duchenne muscular dystrophy [J].
Tsabari, Reuven ;
Simchovitz, Elana ;
Lavi, Eran ;
Eliav, Osnat ;
Avrahami, Ran ;
Ben-Sasson, Shmuel ;
Dor, Talya .
NEUROMUSCULAR DISORDERS, 2021, 31 (09) :803-813
[10]   Dynamic enrichment of Bayesian small-sample, sequential, multiple assignment randomized trial design using natural history data: a case study from Duchenne muscular dystrophy [J].
Wang, Sidi ;
Kidwell, Kelley M. ;
Roychoudhury, Satrajit .
BIOMETRICS, 2023, 79 (04) :3612-3623
1